New hope for Tough-to-Treat skin cancer
NCT ID NCT04971499
Summary
This study is testing a new two-drug combination for people with advanced melanoma that has continued to grow despite receiving standard immunotherapy. Researchers want to find a safe dose and see if adding an oral drug called dapansutrile to the existing drug pembrolizumab can help control the cancer. The trial is for adults with stage III or IV melanoma that cannot be removed by surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke Cancer Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.